Stay updated with breaking news from Mnpr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) was upgraded by equities researchers at Jonestrading from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a $2.00 target price on the stock. Jonestrading’s price objective indicates a potential upside of 226.80% […] ....
By Sabela Ojea Shares of Monopar Therapeutics on Tuesday rose sharply after the company said it received clearance in Australia to begin a phase 1 dosimetry. ....
Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 69,600 shares, a decline of 59.0% from the November 30th total of 169,900 shares. Based on an average daily volume of 1,030,400 shares, the days-to-cover ratio […] ....
Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) traded down 12.2% on Monday . The stock traded as low as $0.40 and last traded at $0.40. 19,524 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 175,884 shares. The stock had previously closed at $0.46. Monopar Therapeutics Price […] ....
Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 279,100 shares, an increase of 231.1% from the May 31st total of 84,300 shares. Based on an average trading volume of 289,300 shares, the days-to-cover ratio is […] ....